Pharmacological Therapy of Benign Prostate Syndrome (BPS)

The document discussed the drug treatment of benign prostatic syndrome (BPS) using alpha1-receptor blockers (alfuzosin, doxazosin, tamsulosin, and terazosin) and 5alpha-reductase inhibitors (dutasteride and finasteride), as well as their combinations. Alpha1-receptor blockers provided rapid symptom relief and were slightly superior to 5alpha-reductase inhibitors, which offered volume-dependent symptom relief and reduced prostate volume-related complications. Combination therapies were found to be superior to monotherapies in patients at high risk for progression, despite increased side effects and costs. The use of plant extracts and anticholinergic substances was not supported by evidence, and the placebo effect was significant for all drugs. The document emphasized the importance of early decision-making regarding drug versus surgical treatment for BPS.